BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  FDA

  With EUA, Novavax Looks to Add Protein-Based Vaccine to U.S. Arsenal

  Novavax is finally submitting an Emergency Use Authorization request to the U.S. Food and Drug Administration for its COVID-19 vaccine candidate, NVX-CoV2373, a protein-based vaccine.

  February 1, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biogen Commits $30M to Genentech Non-Hodgkin’s Lymphoma Antibody

  Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.

  February 1, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  At 50, Microbiologics is Still Setting the Standard and Inspiring Confidence in Science

  Microbiologics, Inc. commemorated its 50th anniversary in 2021 by playing a key role in helping the world manage the COVID-19 pandemic.

  February 1, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Business

  Sarepta and GenEdit Expand Partnership to Transcend Gene Therapy Challenges

  Together, these two companies are combining their strengths to find treatment options for rare neuromuscular diseases.

  February 1, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Takeda Births Oak Hill Bio to Solve Rare Autoimmune Diseases

  Oak Hill Bio has a pipeline that includes two programs with Phase II proof-of-concept data in rare diseases with significant unmet needs.

  February 1, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  ImmunityBio’s Kick-and-Kill Therapy Shows Promise For HIV Patients

  ImmunityBio shared positive results from its clinical trial on its IL-15 superagonist Anktiva (N-803) to treat people living with human immunodeficiency virus (HIV).

  February 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Cortexyme Shuffles Executive Leadership Following Clinical Hold

  Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.

  February 1, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Life Sciences Companies Leverage New Partnerships Against Severe Diseases

  Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.

  February 1, 2022

   · 

  4 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  CEO Kerrie Brady Organizes OcuTerra for Success Against Diabetic Retinopathy

  OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.

  February 1, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  New Direction and New Leadership for Sio, LEO Pharma

  This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.

  February 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN